MELBOURNE, Australia, & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX:CXS)(NASDAQ:CXSP) announced today the first presentation of early clinical data from its registration-directed phase 2/3 clinical study of Ceflatonin® (omacetaxine mepesuccinate) at the Fourth ESH International Conference on Chronic Myeloid Leukaemia (CML) in Mandelieu, France. The presentation by Dr. Franck Nicolini of the Hôpital Edouard Herriot in Lyon, France described the growing problem posed by the T315I point mutation in the treatment of chronic myeloid leukemia (CML) and presented data from four chronic phase T315I positive CML patients who have all benefited from treatment with Ceflatonin.
